Skip to main content
News > News > FDA Approves First-in-Class Oncolytic Virus Immunotherapy for the Treatment of Melanoma

FDA Approves First-in-Class Oncolytic Virus Immunotherapy for the Treatment of Melanoma

October 27, 2015

FDA Approves First-in-Class Oncolytic Virus Immunotherapy for the Treatment of Melanoma

MILWAUKEE, WISCONSIN – This week marks another advance in the fight against skin cancer, as the U.S. Food and Drug Administration (FDA) approved a new immune-based therapy for treating melanoma lesions in the skin and lymph nodes. Amgen’s IMLYGIC (talimogene laherparepvec) commonly referred to as T-VEC, is among a new class of agents known as oncolytic virus immunotherapies. An oncolytic virus is a virus that preferentially infects and kills cancer cells. IMLYGIC is the first therapy in this class to receive FDA approval to treat melanoma….

http://www.sitcancer.org/about-sitc/newsroom/press-releases/fda-approves-imlygic-for-melanoma

 

We Believe

Open Therapeutics crowdsources orphan and dormant therapeutic intellectual properties (IP) to scientists around the world. The goal is advancing research that ordinarily has not generated a public value or been recognized. This approach particularly helps underserved scientists to collaborate with their more financially capable colleagues.

How open science helps researchers succeed:

Open access, open data, open source, and other open scholarship practices are growing in popularity and necessity. However, widespread adoption of these practices has not yet been achieved. One reason is that researchers are uncertain about how sharing their work will affect their careers.

The review of the literature demonstrates that open science is associated with increases in citations, media attention, potential collaborators, job opportunities, and funding opportunities. These findings are evidence that open science practices bring significant benefits to researchers relative to more traditional closed practices.

Secured By miniOrange